linjc16/ctgov huggingface dataset:
Evaluation of a Systematic Approach to Weaning From Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
Prolongation of mechanical ventilation poses serious personal and financial threats to healthcare consumers. The investigators objectives are create and implement an multidisciplinary evidenced-based ventilator-weaning protocol to assess whether a systematic approach compared with the physician's judgment only decreases time spent on the ventilator, complications of mechanical ventilation and length of stay in critical care unit.

Official Title
-----------------
Implantation of a Multidisciplinary Ventilator-weaning Protocol in a Intensive Care Unit of Teaching Hospital of Federal University of Uberlandia

Conditions
-----------------
Weaning Failure, Complication of Respirator [Ventilator]

Intervention / Treatment
-----------------
* Other: Multidisciplinary weaning-ventilator protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: remain in mechanical ventilation for more than 24 hours begin weaning from mechanical ventilation Exclusion Criteria: admitted in the unit already in weaning from mechanical ventilation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Protocol-directed<br>Discontinuation of ventilation was based in multidisciplinary protocol. | Other: Multidisciplinary weaning-ventilator protocol<br>* We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.<br>* Other names: Weaning-ventilator protocol;|
| No Intervention: Usual care<br>Discontinuation of ventilation was left entirely to the discretion of the physicians. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | length of ICU stay (days) | 
| Duration of Weaning From Mechanical Ventilation |  | days | 
| Duration of Mechanical Ventilation |  | days | 
| Length of Intensive Care Unit Stay |  | days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ventilator weaning, protocol
Remote Neurocognitive and Psychological Assessment in PKU

Study Overview
=================
Brief Summary
-----------------
PKU is a rare autosomal recessive condition associated with disruption in dopamine synthesis. Although early diagnosis and treatment prevent the severe impairments associated with untreated PKU, individuals with early-treated PKU (ETPKU) nonetheless experience significant sequelae, including impaired working memory and increased risk for anxiety problems. Past research with other clinical populations (e.g., generalized anxiety disorder) suggests that the two phenomena may be linked, with increased anxiety contributing to poorer WM performance. Currently we propose to initiate an exciting new line of research examining the potential relationship between anxiety and WM in ETPKU. The proposed study will also apply remote neuropsychological performance-based assessment to the study of ETPKU and thus overcoming the geographical limitations/challenges associated with recruitment of participants with this rare disease.

Official Title
-----------------
Remote Assessment of Working Memory and Anxiety in Individuals With Early-Treated Phenylketonuria (PKU)

Conditions
-----------------
Phenylketonurias

Intervention / Treatment
-----------------
* Other: nointervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants with PKU will be included if they were diagnosed as newborns and immediately started on treatment. Exclusion Criteria: Individuals with a history of neurologic compromise or major medical disorder unrelated to PKU (e.g., closed head injury, diabetes, multiple sclerosis) will be excluded. In addition, individuals with PKU will be excluded if they are on a medication called Peg-Valiant/ PEG-PAL/ Pegvaliase/Palynziq.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Individuals with PKU<br>Adults with early-treated PKU | Other: nointervention<br>* Nointervention<br>|
| Individuals without PKU<br>Adults without PKU who are otherwise healthy | Other: nointervention<br>* Nointervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Working Memory performance | Composite score based on multiple working memory-related CANTAB tests | 2.5-3 hrs total over approx 1-3 weeks |
Measurement of Retinal Venous Pressure Under Short-term Low-oxygen Environment

Study Overview
=================
Brief Summary
-----------------
The hypothesis is that the pressure in the retinal veins increases under a short-term lack of oxygen and leads to a decreased blood circulation. On the basis of measurements in the hypobaric chamber this hypothesis should be verified.

Detailed Description
-----------------
Conduct a pilot study to describe and quantify the retinal venous pressure (RVP) in healthy volunteers under conditions of controlled, reduced ambient and oxygen partial pressure in the pressure chamber of the Aeromedical Institute FAI in Dübendorf, Switzerland. Obtaining evidence of the adaptation behavior of the retinal vascular system in controlled, short-term hypoxic changes.

Official Title
-----------------
Measurement of Retinal Venous Pressure (Retinal Venous Pressure RVP) Under Conditions of Reduced Ambient Pressure and Oxygen Partial Pressure

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy Exclusion Criteria: eye diseases systemic diseases term medication (except contraceptives) pregnancy allergies to the ingredients Alcain, Tropicamide and Phenylephrine blood pressure levels except standard (<60 /> 140 mmHg) oxygen saturation (SO2) <90%

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal venous pressure | Quantify the changes in the retinal venous pressure (RVP) | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retinal venous pressure, reduced ambient pressure, oxygen partial pressure, short-term hypoxic changes
Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.

Official Title
-----------------
A Phase 1/2, Multicenter, Non-Randomized, Open Label Clinical Trial of NPC-08 Implant in Patients Undergoing Surgery for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme.

Conditions
-----------------
Malignant Glioma

Intervention / Treatment
-----------------
* Drug: NPC-08


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, aged between 18 and 65 years; Radiographic evidence on cranial MRI of a single contrast-enhancing unilateral supratentorial cerebral tumor; Karnofsky Performance Score of 60 or higher; Willing to practice an effective method of birth control for at least 12 months after wafer implantation surgery; Exclusion Criteria: More than one focus of tumor or tumor crossing the midline, as assessed by coronal cranial MRI scan; Prior radiotherapy to the brain; Prior chemotherapy for the malignant glioma before the baseline evaluation, or patients who were being treated with chemotherapeutic agents; Known hypersensitivity to nitrosoureas; Participation in any other investigational protocol in the previous 6 months for any type of malignancy;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NPC-08<br> | Drug: NPC-08<br>* Polifeprosan 20 with Carmustine 3.85%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival to 12 months |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NPC-08, carmustine, nitrosourea, safety
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib

Study Overview
=================
Brief Summary
-----------------
In order to distinguish between clonal instability driven by imatinib in CML and actual changes with secondary clones induced by imatinib we would like to investigate the karyotype of non-CML patients treated with imatinib such as GIST patients.

Detailed Description
-----------------
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia (Ph) chromosome - a t(9:22) translocation that results in the production of a BCR/ABL fusion protein with Abl kinase activity. Imatinib mesylate (Gleevec) specifically targets a limited set of protein tyrosine kinases - ABL, Arg (Abl-related gene), c-Kit, platelet-derived growth factor receptor (PDGF-R) - and their oncogenic forms, most notably BCR/ABL Imatinib is also a potent inhibitor of a receptor-type c-Kit tyrosine kinase. Therefore imatinib was examined for therapeutic efficacy against malignant gastro-intestinal stromal tumors (GIST) Recent articles have drawn attention to the development of new Ph-negative, cytogenetically unrelated clones after therapy of Ph-positive CML with imatinib. Trisomy 8 and monosomy 7 are the most frequent defects, but other aberrations have also been reported. Some of these cytogenetic abnormalities are associated with acute myeloid leukemia and MDS.

Official Title
-----------------
Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.

Conditions
-----------------
Chronic Myeloid Leukemia, Gastrointestinal Stromal Cell Tumors, Chromosome Abnormality

Intervention / Treatment
-----------------
* Procedure: bone marrow aspiration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: GIST patient on Imatinib for more than 12 months Exclusion Criteria: nil

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: bone marrow aspiration|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
|   presence or absence of genetic abnormality as seen in CML patients on imatinib |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic myeloid leukemia, gastrointestinal stromal cell tumors, chromosome abnormality, imatinib, bone marrow aspiration
The Corona Study of Middle Norway

Study Overview
=================
Brief Summary
-----------------
CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during hospitalization, as well as data from a followup consultation 3 months after discharge.

Official Title
-----------------
The Middle Norway Corona Study - Individual and Genetic Risk Factors for COVID-19 Infection.

Conditions
-----------------
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV-2 Sepsis, SARS CoV 2 Infection

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive SARS CoV-2 infection Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult<br>18+ | Other: No intervention<br>* No intervention, cohort study.<br>|
| Pediatric<br>Under 18 | Other: No intervention<br>* No intervention, cohort study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictors of COVID-19 severity | Primary aim is to assess predictors of severe COVID disease in children and adults | 1 year after inclusion. |
NB-UVB and PUVA Vitiligo Study

Study Overview
=================
Brief Summary
-----------------
To evaluate if the combination of psoralen plus ultraviolet A and narrowband ultraviolet B is more effective than narrowband ultraviolet B alone in the treatment of vitiligo.

Official Title
-----------------
Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Other: Phototherapy
* Other: Phototherapy and Photochemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Vitiligo affecting more than 15% body surface area.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: NB-UVB phototherapy<br>NB-UVB alone | Other: Phototherapy<br> <br> |
| Experimental: phototherapy and photochemotherapy<br>NB-UVB and PUVA | Other: Phototherapy and Photochemotherapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the quantity of repigmentation | Determination the degree of repigmentation measured by the VASI score (Vitiligo area Scoring Index) after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the quality of repigmentation. | Determination of the color of repigmentation, pattern of repigmentation, and the cessation of spread of vitiligo after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone. | Study initiation, 3 months and 6 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitiligo, Phototherapy, Photochemotherapy
Adaptive Coordination in Anaesthesia Teams and Its Relationship to Clinical Performance.

Study Overview
=================
Brief Summary
-----------------
The impact of different coordination patterns on team performance during anesthesia inductions are analyzed using videotapes. These records are examined using various categorization systems (ETHZ), focussing on changes of coordinative behaviour with shifting situational requirements. A rating system comprising multiple categories is used to evaluate team performance. An integrated simulator study facilitates validation of the rating system.

Detailed Description
-----------------
Video tapes and vital parameter readings are recorded with a setup allowing synchronized recordings. Thus, exact timing between events on different data channels can be determined. Data are analyzed for unforeseen events, technical performance, and team coordination / non-technical performance.

Official Title
-----------------
Adaptive Coordination in Anaesthesia Teams and Its Relationship to Clinical Performance. (Cooperative Project ETHZ, OAT, Prof. G. Grote, and IfA/USZ; Founding by Swiss National Science Foundation to Both Institutions)

Conditions
-----------------
Anesthesia Team Coordination

Intervention / Treatment
-----------------
* Behavioral: Observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Anesthesia personnel with at least 3 months practical anesthesia experience Patients undergoing surgical procedures Exclusion criteria: Not meeting inclusion criteria Lack of consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Simulation of anesthesia induction with critical incidents: Analysis of technical and non-technical performance (15 Teams) | |
| 2<br>Analysis of technical and non-technical performance in live anesthesia inductions (40 teams) | |
| 3<br>Simulation of anesthesia inductions with advanced simulated critical incidents or events and analysis of technical and non-technical performance (max. 50 teams) | Behavioral: Observational study<br>* Observational (descriptive) study of technical and non-technical performance<br>* Other names: video analysis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Molecular Mechanisms of Tooth Eruption

Study Overview
=================
Brief Summary
-----------------
The main objective is to study the expression of molecules involved in tooth morphogenesis and eruption in healthy patients, and then to compare them with the results in patients with abnormalities of eruption (results obtained via a collection of biological samples of rare diseases already authorized).

Official Title
-----------------
Molecular Mechanisms of Tooth Eruption

Conditions
-----------------
Tooth Eruption

Intervention / Treatment
-----------------
* Procedure: Tooth extraction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient over 12 years old who has given his consent Patient whose legal representatives have given their consent for the use of operating waste destined for incineration Patient undergoing oral surgery at the University Hospitals of Strasbourg, at the origin of the production of surgical waste such as teeth and bone fragments Patient affiliated to a social security system Exclusion Criteria: Refusal to participate Patient with chronic systemic pathology Patient under long-term drug treatment Patient presenting a rare pathology with oral manifestation Patient with a history of chemotherapy or head and neck radiotherapy Non-French speaking patient / inability to give informed information Patient under guardianship, curatorship or legal protection

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal tooth eruption<br> | Procedure: Tooth extraction<br>* Tooth extraction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression and localization of molecules involved in tooth eruption | Tissues are collected at the time of surgery and transferred during the day to the laboratory for analysis | During surgery |